Serum tPSA, cPSA, related density parameters and chromogranin A as predictors of positive margins after radical prostatectomy

Anticancer Research

Volumn 27, Issue 4 C, 2007, Pages 2817-2821

  Custovic, Zajim ^a,c   Kraus, Ognjen ^b   Tomaskovic, Igor ^b   Tarle, Marko ^b  

^a Dubrovnik General Hospital   (Croatia)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^c Hospital of Dubrovnik   (Croatia)

Author keywords

Blood CgA level; Localized prostate cancer; Positive post surgical margins; PSA ACT and density parameters; Serum t PSA

Indexed keywords

CHROMOGRANIN A; CHYMOTRYPSIN INHIBITOR; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CALCULATION; CANCER LOCALIZATION; CANCER STAGING; CLINICAL ARTICLE; CORRELATION ANALYSIS; GLEASON SCORE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; NOMOGRAM; PELVIS LYMPHADENECTOMY; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; ULTRASOUND;

AGED; ALPHA 1-ANTICHYMOTRYPSIN; CHROMOGRANIN A; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 34547751529     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Sokoll LJ and Chan D: Prostate-specific antigen and human glandular kallikrein 2 in early detection of prostate cancer. J Urol 169: 445-457, 2003.
2. Ellis WJ, Chetner MP, Preston SD and Brawer M: Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol 52: 1520-1525, 1994.
3. Stewart AK, Bland KI, McGinnis LS Jr, Morrow M and Eyre HJ: Clinical highlights from the National Cancer Data Base, CA Cancer J Clin 50: 171-183, 2000.
4. Epstein JI, Pizov G and Walsh PC: Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71: 3582-3593, 1993.
5. Ljilja H, Cocket AT and Abrahamsson PA: Prostate specific antigen predominatly forms a complex with α1-antichymotripsin in the blood. Cancer 37: 230-234, 1992.
6. Ishida E, Nakamura M, Shimada K, Kishi M, Nakaoka S and Konishi I: Distribution and secretory pathways of prostate specific antigen, alpha 1-antichymotrypsin and prostate secretory granules in prostate cancers. Pathol Int 53: 415-422, 2003.
7. Sokoll L, Mangold L, Partin A et al: Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 man. Urology 60 Suppl: 1-18, 2002.
8. Ornstein DK, Englert C, Gillespie JW, Paweletz CP, Lineahan WM and Emmert-Buck MR: Characterization of intracellular prostate-specific antigen from laser capture microdissected benign and malignant prostatic epithelium. Clin Cancer Res 6: 353-356, 2000.
9. Djavan B, Remzi M, Zlotta A et al: Complexed prostate specific antigen, complexed prostate specific density of total and transitional zone, complexed/total prostate specific antigen ratio, free to total prostate specific antigen ratio, density of total and transition zone prostate specific antigen: results of the prospective multicenter Europian trial. Urology 60 Suppl: 1-4, 2002.
10. Oremek GM, Sapoutzis N, Eden F and Jonas D: Complexed PSA in routine diagnosis. Anticancer Res 23: 975-977, 2003.
11. Piironen T, Petterson K, Suonpaa et al: In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha-1-antichymotrypsin in blood samples. Urology 48(6A Suppl): 81-87, 1996.
12. Allard WJ, Zhou Z and Yeung KK: Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem 44: 1216-1223, 1998.
13. Horninger W, Reissigl A, Klocker H et al: Improvement of specificity in PSA-based screening by using PSA-transition zone density and percent free PSA in addition to total PSA levels. The Prostate 37(3): 133-137, 1998.
14. Ahel ZM, Kovacic K and Tarle M: Cross-correlation of serum Chromogranin A, %-F-PSA and bone scans in prostate cancer diagnosis. Anticancer Res 21: 1363-1366, 2001.
15. Partin AW, Mangold LA, Lamm DM et al: Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 58: 843-848, 2001.
16. Walsh PC: Radical prostatectomy for localized prostate cancer provide durable cancer control with excellent quality of life: a structured debate. J Urol 163: 1802-1807, 2000.
17. Hodgson D, Warde P and Gospodarowitz M: The Management of locally advanced prostate cancer. Urol Oncol 4: 3-12, 1998.
18. Van Poppel, Goethuys H, Callewart P et al: Radical prostatectomy can provide cure for well-selected clinical T3 stage prostate cancer. Eur Urol 38: 372-379, 2000.
19. Defos LJ, Nakada S, Burton DW, di Sant Agnese PA, Cockett AT and Abrahamsson PA: Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology 48: 58-62, 1996.
20. Ahel MZ, Kovacic K, Kraljic I and Tarle M: Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients. Anticancer Res 21: 1475-1480, 2001.
21. Stebman UA, Leionen J, Alfthan H, Ranniko S, Tuhkanen K and Alfthan O: A complex between prostate-specific antigen and α1-antichymotripsin is major form of prostate-specific antigen in the serum of patients with prostatic cancer: asasay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222-226, 1991.
22. Tarle M: Serum chromogranin A in monitoring metastatic prostate cancer patients. Anticancer Res 19: 5663-5666, 1999.
23. Grimaldi F, Valotto C, Barbine G, Visentini D, Trianni A, Cerutto MA and Zattoni F: The possible role of chromogranin A as a prognostic factor in organ-confined prostate cancer. Int J Biol Markers 21(4): 229-234, 2006.